27 assets in Adenocarcinoma

Therapeutic assets addressing Adenocarcinoma, rated under Floatz methodology v0.2 and sorted by current rating.

Asset	Sponsor	Phase	Rating
Cis-Diamminedichloroplatinum Ii Adenocarcinoma	Mayo Clinic	P4	BBB (76)
Carboplatin Adenocarcinoma	Blueprint Medicines Corporation	P4	BBB (74)
Irinotecan Adenocarcinoma	University of Chicago	P2	BBB (72)
Cyclophosphamide Adenocarcinoma	M.D. Anderson Cancer Center	P3	BB (70)
Fluorouracilum Adenocarcinoma	University of Chicago	P2	BB (68)
Epirubicin Adenocarcinoma	M.D. Anderson Cancer Center	P3	BB (66)
Pembrolizumab Adenocarcinoma	M.D. Anderson Cancer Center	P3	BB (65)
Osimertinib Adenocarcinoma	Blueprint Medicines Corporation	P2	BB (64)
Oxaliplatin Adenocarcinoma	University of Chicago	P2	BB (64)
Docetaxel Adenocarcinoma	University of Chicago	P2	B (63)
Fludarabine Adenocarcinoma	M.D. Anderson Cancer Center	P2	B (59)
Palbociclib Adenocarcinoma	NiKang Therapeutics, Inc.	P2	B (57)
Immunoglobulin G4, Anti-(Human Programmed Cell Death Protein 1) (Human Monoclonal Regn2810 Heavy Chain), Disulfide With Human Monoclonal Regn2810 .Kappa.-Chain, Dimer Adenocarcinoma	Gulam Manji	P2	CCC (53)
Motixafortide Adenocarcinoma	Gulam Manji	P2	CCC (53)
NKT2152 Adenocarcinoma	NiKang Therapeutics, Inc.	P2	CCC (53)
(R)-(1-(4-Fluorophenyl)-6-((1-Methyl-1H-Pyrazol-4-Yl)Sulfonyl)-1,4,5,6,7,8-Hexahydro-4Ah-Pyrazolo(3,4-G)Isoquinolin-4A-Yl)(4-(Trifluoromethyl)Pyridin-2-Yl)Methanone Adenocarcinoma	Corcept Therapeutics	P2	CCC (53)
Young Til Adenocarcinoma	National Cancer Institute (NCI)	P2	CCC (53)
Triadeno Vaccine Adenocarcinoma	National Cancer Institute (NCI)	P2	CCC (52)
Trop2-Car-Nk Adenocarcinoma	M.D. Anderson Cancer Center	P1/2	CC (47)
Nogapendekin Alfa Inbakicept Adenocarcinoma	National Cancer Institute (NCI)	P2	CC (44)
Blu-701 Adenocarcinoma	Blueprint Medicines Corporation	P1	CC (43)
Immunoglobulin (H-Gamma1_L-Kappa)_Scfvkh-G1(H-Ch2-Ch3), Anti-[Homo Sapiens Klk2 (Kallikrein-2, Kallikrein Related Peptidase 2, Kallikrein 2 Prostatic) And Anti-[Homo Sapiens Cd3E (Cd3 Epsilon, Leu-4)], Homo Sapiens And Humanized Monoclonal Antibody, Bispecific, Bivalent Adenocarcinoma	Janssen Research & Development, LLC	P1	CC (43)
Jnj-69086420 Adenocarcinoma	Janssen Research & Development, LLC	P1	CC (43)
Lenvatinib Adenocarcinoma	M.D. Anderson Cancer Center	P1	CC (43)
Pebezertinib Adenocarcinoma	Blueprint Medicines Corporation	P1	CC (43)
Sasanlimab Adenocarcinoma	NiKang Therapeutics, Inc.	P2	C (34)